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Background: Distinguishing new from recrudescent infections in post-treatment episodes of malaria is standard in
anti-malarial drug efficacy trials. New infections are not considered malaria treatment failures and as a result, the
prevention of subsequent episodes of malaria infection is not reported as a study outcome. However, in moderate
and high transmission settings, new infections are common and the ability of a short-acting medication to cure an
initial infection may be outweighed by its inability to prevent the next imminent infection. The clinical benefit of
preventing new infections has never been compared to that of curing the initial infection.
Methods: Children enrolled in a sulphadoxine-pyrimethamine efficacy study in Blantyre, Malawi from 1998–2004
were prospectively evaluated. Six neutral microsatellites were used to classify new and recrudescent infections in
children aged less than 10 years with recurrent malaria infections. Children from the study who did not experience
recurrent parasitaemia comprised the baseline group. The odds of fever and anaemia, the rate of haemoglobin
recovery and time to recurrence were compared among the groups.
Results: Fever and anemia were more common among children with parasitaemia compared to those who
remained infection-free throughout the study period. When comparing recrudescent vs. new infections, the
incidence of fever was not statistically different. However, children with recrudescent infections had a less robust
haematological recovery and also experienced recurrence sooner than those whose infection was classified as new.
Conclusions: The results of this study confirm the paramount importance of providing curative treatment for all
malaria infections. Although new and recrudescent infections caused febrile illnesses at a similar rate, recurrence
due to recrudescent infection did have a worsened haemological outcome than recurrence due to new infections.
Local decision-makers should take into account the results of genotyping to distinguish new from recrudescent
infections when determining treatment policy on a population level. It is appropriate to weigh recrudescent malaria
more heavily than new infection in assessing treatment efficacy.
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Anti-malarial drug efficacy studies serve several purposes.
They are used to assess drug efficacy and safety for licens-
ing, for comparison of efficacy across different settings,
and sometimes for validation of markers of drug resist-
ance. For any of these purposes, controlling for differences
in malaria transmission intensity is essential in drug
efficacy studies. Episodes of recurrent parasitaemia follow-
ing treatment may be due to recrudescence of the initial
infection, reflecting failure of the drug to clear the infec-
tion; or, they may be due to new infections that occurred
during the follow-up period. Genotyping of polymorphic
genes or short tandem repeats (microsatellites) is used to
distinguish recrudescent from new infections. New infec-
tions are not considered a failure of the curative efficacy
of the drug. This practice of polymerase chain reaction
(PCR) correction of efficacy, however, leads to the dis-
counting of the post-treatment prophylactic efficacy that
can be an important secondary benefit of drug treatment,
especially with longer-acting anti-malarial drugs. The abil-
ity of a drug to prevent new infections for weeks or even
months after an acute treatment episode is not taken into
account when measuring efficacy in the standard way. A
drug that appears to cure the initial infection but offers no
protection against the next infection may appear to have
the greatest clinical success rate, but in higher transmis-
sion settings, new infections are common and the ability
of a short-acting medication to cure an initial infection
may be outweighed by its inability to prevent the next
imminent infection.
One way to determine the relative importance of pre-
venting new versus recrudescent infections is to compare
the clinical burden of each of these types of infection. If
one type is more likely to cause fever (the most common
clinical manifestation of malaria) or increase the risk of
anaemia, then it may be possible to determine if prevent-
ing recrudescent infections is as important as curing the
original one. In a meta-analysis conducted by Olliaro and
colleagues, the results of 13 studies in Africa across differ-
ent countries and using different treatments showed that
individuals with new infections developed fever sooner
than those who experienced recrudescent infections, al-
though the risk was high in both groups [1]. However,
the findings among the different studies were heteroge-
neous and when multivariate analysis was performed, risk
of fever was only associated with the parasite density of
the recurrent infection and was inversely related to age.
The authors did not review the effect on haemoglobin
concentration, although anaemia is one of the common
morbidities associated with malaria.
Long-standing surveillance of antimalarial drug efficacy
in a stable population provides a unique opportunity to
compare the clinical presentation of new and recrudescent
infections. The efficacy of sulphadoxine-pyrimethamine(SP) was monitored over a six-year period in a large co-
hort of children in Malawi, an area of moderate perennial
malaria transmission. The study took place towards the
end of the period when SP was Malawi's national first-line
treatment for uncomplicated malaria, when SP was mod-
estly efficacious, and when both new and recrudescent
infections were expected to occur.
Methods
Data collection
Blood samples were obtained for this study from February
1998 to June 2004 at the Ndirande Health Centre in
Blantyre, Malawi [2]. Study participants were children
aged five months through 10 years who had symptoms of
malaria and Plasmodium falciparum detected in their per-
ipheral blood smear by microscopy. The day of study en-
rolment was designated day 0 and participants were given
standard treatment doses of SP (500 mg sulphadoxine and
25 mg pyrimethamine per tablet, ¼ tablet per 5 kg weight).
Follow-up took place on days 1, 2, 3, 7, 14, and 28 and any
time a participant was ill prior to day 28. At each visit, a
malaria smear was obtained, haemoglobin concentration
was measured (HemoCue Angelholm, Sweden) and drops
of blood were collected on filter paper. Specimens from
participants who were found to have recurrent parasit-
aemia from day 14 through 28 underwent genotyping as
described below. Children who were febrile at the time of
recurrent parasitaemia were treated with halofantrine res-
cue therapy and terminated from follow-up. Participants
with asymptomatic infections were followed according to
the study schedule and were provided rescue therapy
when they developed fever or reached day 28. Participants
who were successfully treated and did not experience
recurrent infection through day 28 were included as the
baseline group. The study protocol was approved by the
University of Malawi College of Medicine Research
and Ethics Committee and the University of Maryland
Baltimore Institutional Review Board.
DNA was extracted from the dried blood spots on fil-
ter papers using the Qiagen BioRobot Universal System
with the QIAamp Investigator BioRobot Kit (German-
town, MD, USA) for day 0 and the day(s) of recurrent
parasitaemia. Based on previous studies within the
authors’ research group, the six microsatellites with the
greatest genetic diversity among the 12 neutral microsa-
tellites, that have been reported previously to adequately
discriminate among parasites from a variety of settings,
were used [3]. The markers Poly alpha, PfPK2, TA81,
ARA2, TA87, and TA40 were amplified using a hemi-
nested PCR approach, described in detail on the refer-
enced website [4]. Samples were processed for capillary
electrophoresis using an Applied Biosystems 3730XL
high-throughput 96-capillary DNA sequencer and soft-
ware (Foster City CA, USA).
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Capillary electrophoresis output files were analysed
using Genemapper 4.0 (Applied Biosystems, Foster City
CA, USA) with default microsatellite analyses settings.
Genomic control strains, 3D7 and HB3 (ATCC-MR4,
Manassas VA, USA) were included to determine the
characteristic morphology of peaks for each marker and
to control for slight variations in capillary electrophor-
esis. Only peaks with the characteristic morphology
above the threshold of 100 relative fluorescent units
were scored and companion peaks were omitted. Alleles
were sized by manual inspection of each electrophero-
gram and then normalized against the 3D7 control. The
adjusted peak sizes were rounded to the nearest three
nucleotide repeat size using a custom Perl script. Sam-
ples were analysed once the data had been adjusted and
binned. Details about the PCR and scoring protocol are
published on the investigators’ website [4].
Genotype classification
Parasite genotypes present on the day of recurrent mal-
aria infection were compared to genotypes present on
day 0. Samples with detectable alleles for five or six
microsatellite loci were considered complete and were
classified as new, recrudescent or uninterpretable. A re-
crudescent infection had matching alleles at every locus
or all but one locus when comparing genotypes on day 0
and day of recurrent parasitaemia. We allowed for the ab-
sence of a matching allele at one locus because with poly-
clonal infections, alleles may occasionally be undetectable
[5]. A new infection had ≤3 microsatellite loci with
matching alleles between day 0 and the day of recurrent
parasitaemia. Uninterpretable samples had four out of six
microsatellite loci with matching alleles between day 0
and day of recurrent parasitaemia. Multiplicity of infec-
tion (MOI) was defined as the highest number of alleles
found at a single locus and represents the number of
simultaneous infections carried in a patient.
Clinical definitions
Fever was defined as an axillary temperature ≥37.5°C at the
time of evaluation at the study clinic. Mild anaemia was
defined as a haemoglobin concentration <11.0 g/dL and
moderate anaemia as a haemoglobin level of <7.0 g/dL.
Haematological recovery was calculated by subtracting the
day 0 haemoglobin concentration from the haemoglobin
concentration on the day of recurrent infection.
Statistical analysis
Data were analysed in STATA 12.0 (StataCorp, College
Station, TX, USA). Baseline characteristics including
age, geometric mean parasite density and haemoglobin
concentration among participants who experienced no
recurrent infection, recrudescent infection and newinfections were compared by ANOVA. MOI was only
measured in samples from participants with recurrent
infection. To assess clinical outcome at the time of
recurrence or at the end of the study for participants
who did not experience recurrent infection, incidence of
fever and anaemia, mean haemoglobin and mean
change in haemoglobin from baseline were compared
between the three groups. The relationship between re-
current infection status and these key clinical outcomes
were assessed using logistic and linear regression, using
participants without recurrent infection as the referent.
Logistic regression and Student’s t-test were used to
compare odds ratios and means between new and recru-
descent infections. Multivariate logistic regression was
used to assess the relationship of each clinical factor to
new compared to recrudescent infection. In the multi-
variate regression, year was included in addition to the
other variables analysed individually. When more than
one episode of recurrent parasitaemia occurred in an in-
dividual, each pair from day 0 and the day of failure was
treated independently and the Huber/White/sandwich
estimator of variance was used to control for non-
independence of measures within a single individual.
The analyses were subsequently repeated using only the
first or only the final episode of parasitaemia for indivi-
duals with more than one episode or recurrent infec-
tion. Kaplan-Meier curves to analyse time to first
recurrent infection and symptomatic infection by recur-
rent infection classification were compared using the
log rank test.
Results
Over the six-year study period, 279 participants were fol-
lowed for 28 days with no recurrent infection and 265 had
episodes of recurrent parasitaemia between days 14 and
28. Microsatellites were amplified from initial and recur-
rent infections in 222 pairs of infections from 195 chil-
dren. The infections were classified as 119 recrudescent
infections, 84 new infections and 19 with uninterpretable
results. Baseline characteristics of the three groups are
presented in Table 1. There was no difference in age be-
tween the children who had no recurrent infection, recru-
descent infection or new infection. Initial parasite density
and haemoglobin concentration did not differ between
subjects who later developed new compared to recrudes-
cent infections (p= .10 and p= .15, respectively).Clinical symptoms in patients with recrudescence versus
reinfection
Temperature was recorded for all participants at the
time of recurrent infection and for 277/279 of the parti-
cipants who had successful treatment. Measurement of
haemoglobin at the time of recurrent parasitaemia or
Table 1 Baseline characteristics of participants who were successfully treated for their infection and those that
experienced recrudescent or new infections: mean (95% confidence interval)
No recurrent infection Recrudescent New infection P value
Age in months 33.9 (30.6-37.2) 33.0 (28.7-37.3) 35.7 (29.5-41.9) .8
Parasites/mm3 7,365 (5408–10,029) 26,291 (17,508-39,480) 15,331 (9,164-25,649) .002
Haemoglobin in gm/dL 9.8 (9.6-10.1) 9.3 (9.0-9.6) 9.0 (8.5-9.4) .009
Multiplicity of infection Not available 3.1 (2.8-3.5) 2.5 (2.3-2.9) .03
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participants.
Table 2 shows the prevalence of fever and anaemia and
the mean haematological recovery among children who
experienced no recurrent malaria, recrudescent infection
and new infection. Fever and anaemia were more common
among children with parasitaemia compared to those with-
out infection. The haematological recovery did not differ
between the groups when measured in univariate analysis.
Only five patients had moderate anaemia on the day of
recurrent parasitaemia and they were equally distributed
among recrudescent and new infections (two and three,
respectively).
In multivariate analysis, fever and the presence of mild
anaemia were not associated with the classification of new
vs. recrudescent infection. However, children with new
infection had an improved haematological recovery com-
pared to those who experienced recrudescent infections,
after controlling for other confounding variables.Table 2 Clinical characteristics at the time of recrudescent an
the study without recurrent infection
Distribution Odds ratio (95% CI) univariate P valu
Proportion (%)
Fever
No 11/277(3.9) Referent
Recrudescent 26/119 (21.8) 6.8 (3.2-14.3) <.001
New 13/84 (15.4) 4.4 (1.9-10.3) .001
Anaemia
No 137/275 (49.8) Referent
Recrudescent 81/117 (69.2) 2.3 (1.4-3.7) .001
New 54/83 (65.1) 1.9 (1.1-3.2) .017
Mean (95% CI)
Change in haemoglobin
No .9 (.8-1.2)
Recrudescent .7 (.4-1.0) .2
New 1.2 (.7-1.6) .4
Multiplicity of infection
No N/A
Recrudescent 2.7 (2.3-3.0)
New 2.3 (2.1-2.6) .1First parasitemia occurred sooner for recrudescent com-
pared to new infection (Figure 1, p= .03). The time to
febrile parasitemia was the same for both groups (p= .14).
Twenty-one participants had two or three time points
when recurrent parasitaemia was detected and had inter-
pretable molecular results. Twelve children had repeated
episodes of recrudescent infections, five had repeated epi-
sodes of new infections, three had new followed by recru-
descent infections and one had a recrudescent followed by
a new infection. As a sensitivity analysis, the analyses were
repeated including only the first recurrent infection and
again including only the final recurrent infection. The point
estimates for the odds ratios were almost identical, al-
though the confidence intervals were wider, as expected
with a smaller sample size.
Discussion
To the authors’ knowledge, this is the first study to suggest
a benefit of preventing recrudescent compared to newd new infection compared to participants at the end of
e Odds ratio (95% CI) Multivariate Recrudescent vs. new P value
Referent
.6 (.2-1.5) .27
Referent
1.5 (.7-3.2) .34
Referent
1.3 (1.1-1.6) .01
Referent
.8 (.6-1.0) .05
Figure 1 Kaplan-Meier survival curves for time to recurrent infection, comparing new versus recrudescent infections.
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children with malaria infection than among those without.
However, this study demonstrated that recrudescent infec-
tions are associated with worsened haematological out-
comes compared to a new malaria infection acquired after
successful treatment. Also, recrudescent infections occur
sooner after treatment, leading to an overall increase in the
incidence of infections. Thus, although new and recrudes-
cent infections are clinically indistinguishable, curing the
initial infection, even if a new infection occurs, improves
the overall health of the patient.
Impaired haematological recovery in children with recru-
descent parasitaemia is an objective measure and essential
to the overall health of the population. With persistent in-
fection, even when it is microscopically undetectable, on-
going inflammation and erythrocyte destruction interferes
with the recovery of the red blood cells [6]. Interestingly, in
almost all cases, haemoglobin levels increased despite the
failure to completely cure the infection.
In this study, age was not a risk factor for recurrent in-
fection in general nor was it associated with the classifica-
tion of new versus recrudescent infection. This may be
due to the intensity of transmission at the study site lead-
ing to early acquisition of immunity or it may be attribu-
ted to the homogeneity in the age of the participants.
As expected, infections were polyclonal within indivi-
duals in this study. At baseline measurement, patients
with higher MOI at the time of recurrence were more
likely to be classified as having a recrudescent infection.
This may be a true biological phenomenon or it may be
due to chance. When a participant’s MOI at baseline or
at the time of reinfection was high, new infections could
have been misclassified as recrudescent infections be-
cause some alleles from a new parasite genotype mayhave matched between the original and recurrent infec-
tion by chance. Infection with multiple malaria parasite
strains may have had a greater probability of containing
one or more malaria strains that were resistant to treat-
ment, leading to a recrudescent infection.
Any genotyping technique may misclassify infections.
If a parasite genotype is present, but below the level of
detection at the initial infection and then grows to
detectable levels at the time of recurrent infection, it
may be classified as a new infection even though it was
present initially. Alleles were identified using capillary
electrophoresis, a method that is highly sensitive and
less likely than other genotyping methods to fail to
detect minority populations [7]. Another limitation was
the inability to discern haplotypes. Consequently, poly-
clonal infections that shared the same collection of
alleles between the initial and recurrent infections may
have appeared to be recrudescent infections, even though
the haplotype profiles for the parasites in the recurrent
infection were different.
The most notable limitation of this study is that these
SP efficacy results may not be applicable to the currently
used artemisinin-based combination therapies. SP was a
failing drug at the time of this study, which resulted in
more recrudescent infections than would be expected in a
current artemisinin combination therapy drug efficacy
study. It is also possible that current, more effective drugs
keep recrudescent infections at a lower density of parasit-
aemia, which may produce a different clinical presentation
compared to patients treated with SP. In addition, in
current protocols for assessment of anti-malarial drug
efficacy, all episodes of recurrent parasitemia are treated
with rescue therapy, regardless of symptoms. As a result,
this experiment is unlikely to be repeated.
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frequently interfere with assessment of a drug’s efficacy in
clearing the initial infection, using molecular methods to
distinguish new from recrudescence provides useful infor-
mation. This study’s results indicate that treating clinical
malaria with drugs that provide sterile cure is the most
beneficial to the patient when compared to suppressive
treatment that fails to eliminate all asexual parasites from
the blood even while preventing subsequent infections.
The results of this study confirm the paramount import-
ance of providing effective treatment of all malaria infec-
tions. If malaria infection occurs several weeks after the
initial treatment, full parasitological cure followed by a new
infection is better for patients than suppressive treatment
with persistent sub-patent infection that reaches detectable
levels again. Thus, anti-malarial drugs that provide pro-
longed prophylaxis but poor curative efficacy will have a
long-term detrimental effect on the health of children
who suffer from anaemia due to malaria. However,
new infections are far from benign. They are just as
likely as recurrent ones to cause febrile illnesses in chil-
dren, prompting treatment-seeking behaviour and leading
to further burden on the health care system.
Conclusion
In areas of continuous exposure to malaria, distinguishing
new from recrudescent infections in cases of recurrent
parasitaemia after treatment has important clinical impli-
cations. Although new and recrudescent infections cause
febrile illnesses at a similar rate, recurrence due to recru-
descent infection is associated with higher rates of
anaemia than new infections and a shorter parasite-free
interval. Local decision-makers should take into account
the results of genotyping to distinguish new from recru-
descent infections when determining treatment policy on
a population level. It is appropriate to weigh recrudescent
malaria more heavily in assessing treatment efficacy and if
two drugs have similar rates of recurrent infections, the
one that has higher curative efficacy should be selected
over one that allows for more recrudescent infections.
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